Table 2 Univariate and multivariate Cox proportional hazards analyses for PFS.

From: Prognostic impact of extracellular volume fraction derived from equilibrium contrast-enhanced CT in HCC patients receiving immune checkpoint inhibitors

Characteristics

Univariate analysis

Multivariate analysis

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Age (years)

< 60

Reference

Ā 

Reference

Ā 

≄ 60

0.719 (0.490–1.055)

0.092

0.716 (0.477–1.077)

0.109

Sex

Female

Reference

Ā Ā Ā 

Male

0.963 (0.566–1.641)

0.891

Ā Ā 

BMI(kg/m2)

0.973 (0.914–1.036)

0.394

Ā Ā 

HBV infection

No

Reference

Ā Ā Ā 

Yes

0.872 (0.598–1.272)

0.477

Ā Ā 

Types of ICIs

PD-1

Reference

Ā Ā Ā 

PD-L1

0.625 (0.296–1.321)

0.218

Ā Ā 

Combined with TKIs

No

Reference

Ā Ā Ā 

Yes

1.182 (0.812–1.722)

0.383

Ā Ā 

Tumor maximum diameter (cm)

1.044 (0.999–1.090)

0.054

1.010 (0.961–1.062)

0.691

Tumor number

≤ 3

Reference

Ā Ā Ā 

> 3

1.353 (0.839–2.181)

0.215

Ā Ā 

PVTT

No

Reference

Ā 

Reference

Ā 

Yes

1.692 (1.143–2.504)

0.009

1.247 (0.773–2.013)

0.365

Lymph node metastasis

No

Reference

Ā Ā Ā 

Yes

1.234 (0.808–1.884)

0.331

Ā Ā 

BCLC stage

B

Reference

Ā 

Reference

Ā 

C

1.998 (1.357–2.944)

< 0.001

1.694 (1.055–2.719)

0.029

Child-Pugh

A

Reference

Ā Ā Ā 

B

0.987 (0.537–1.813)

0.965

Ā Ā 

ECOG PS

0

Reference

Ā Ā Ā 

≄ 1

1.207 (0.782–1.864)

0.396

Ā Ā 

NLR

1.088 (1.000–1.183)

0.049

1.091 (0.983–1.211)

0.101

PLR

1.003 (1.001–1.004)

0.005

1.001 (0.999–1.003)

0.385

ALT(U/L)

1.000 (0.999–1.002)

0.648

Ā Ā 

AST(U/L)

1.001 (0.999–1.003)

0.289

Ā Ā 

TB (µmol/L)

1.004 (0.989–1.019)

0.624

Ā Ā 

Albumin (g/L)

0.994 (0.957–1.032)

0.745

Ā Ā 

PT (s)

0.932 (0.809–1.074)

0.329

Ā Ā 

Urea nitrogen (mmol/L)

0.968 (0.868–1.079)

0.558

Ā Ā 

Creatinine (µmol/L)

0.996 (0.985–1.008)

0.512

Ā Ā 

AFP (ng/mL)

< 400

Reference

Ā Ā Ā 

≄ 400

1.291 (0.881–1.891)

0.190

Ā Ā 

Liver ECV group

Lower liver ECV

Reference

Ā Ā Ā 

Higher liver ECV

1.198 (0.823–1.744)

0.346

Ā Ā 

Tumor ECV group

Lower tumor ECV

Reference

Ā 

Reference

Ā 

Higher tumor ECV

0.502 (0.340–0.742)

< 0.001

0.471 (0.314–0.709)

< 0.001

  1. Significant values are given in bold.
  2. PFS progression-free survival, ECV extracellular volume, CI confidence interval, BMI body mass index, HBV hepatitis B virus, ICIs immune checkpoint inhibitors, TKIs tyrosine kinase inhibitors, PVTT portal vein tumor thrombosis, BCLC Barcelona clinic liver cancer, ECOG PS eastern cooperative oncology group physical status, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, ALT alanine transaminase, AST aspartate transaminase, TB total bilirubin, PT prothrombin time, AFP alpha-fetoprotein.